{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:50:32Z","timestamp":1790470232194,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["2K12CA133250-06A1"],"award-info":[{"award-number":["2K12CA133250-06A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P01 CA214272"],"award-info":[{"award-number":["P01 CA214272"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P01 CA214272"],"award-info":[{"award-number":["P01 CA214272"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P01 CA214272"],"award-info":[{"award-number":["P01 CA214272"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"crossref","award":["2020YIA-6689186701"],"award-info":[{"award-number":["2020YIA-6689186701"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"crossref"}]},{"name":"American Brain Tumor Association Basic Research Fellowship sponsored by an Anonymous Corporate Partner"},{"name":"Pelotonia IDEA grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mantle cell lymphoma (MCL) is a rare, highly heterogeneous type of B-cell non-Hodgkin\u2019s lymphoma. The sumoylation pathway is known to be upregulated in many cancers including lymphoid malignancies. However, little is known about its oncogenic role in MCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Levels of sumoylation enzymes and sumoylated proteins were quantified in MCL cell lines and primary MCL patient samples by scRNA sequencing and immunoblotting. The sumoylation enzyme SAE2 was genetically and pharmacologically targeted with shRNA and TAK-981 (subasumstat). The effects of SAE2 inhibition on MCL proliferation and cell cycle were evaluated using confocal microscopy, live-cell microscopy, and flow cytometry. Immunoprecipitation and orbitrap mass spectrometry were used to identify proteins targeted by sumoylation in MCL cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MCL cells have significant upregulation of the sumoylation pathway at the level of the enzymes SAE1 and SAE2 which correlated with poor prognosis and induction of mitosis associated genes. Selective inhibition of SAE2 with TAK-981 results in significant MCL cell death in vitro and in vivo with mitotic dysregulation being an important mechanism of action. We uncovered a sumoylation program in mitotic MCL cells comprised of multiple pathways which could be directly targeted with TAK-981. Centromeric localization of topoisomerase 2A, a gene highly upregulated in SAE1 and SAE2 overexpressing MCL cells, was lost with TAK-981 treatment likely contributing to the mitotic dysregulation seen in MCL cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study not only validates SAE2 as a therapeutic target in MCL but also opens the door to further mechanistic work to uncover how to best use desumoylation therapy to treat MCL and other lymphoid malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40164-022-00293-y","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T05:08:01Z","timestamp":1657688881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells"],"prefix":"10.1186","volume":"11","author":[{"given":"Walter","family":"Hanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpa","family":"Lata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liudmyla","family":"Tsyba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley W.","family":"Blaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Huszar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoBeth","family":"Helmig-Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan S.","family":"Schrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Keung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Prouty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany L.","family":"Mundy-Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Chen-Kiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami","family":"Maddocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"issue":"3","key":"293_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.17116\/patol20198103159","volume":"81","author":"IL Polyatskin","year":"2019","unstructured":"Polyatskin IL, Artemyeva AS, Krivolapov YA. Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition):lymphoid tumors. Arkh Patol. 2019;81(3):59\u201365.","journal-title":"Arkh Patol"},{"issue":"6","key":"293_CR2","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1080\/10428194.2018.1542144","volume":"60","author":"A Mareckova","year":"2019","unstructured":"Mareckova A, Malcikova J, Tom N, Pal K, Radova L, Salek D, et al. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. Leuk Lymphoma. 2019;60(6):1420\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"5\u20136","key":"293_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","volume":"25","author":"P Yang","year":"2018","unstructured":"Yang P, Zhang W, Wang J, Liu Y, An R, Jing H. Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Ther. 2018;25(5\u20136):129\u201340.","journal-title":"Cancer Gene Ther"},{"issue":"19","key":"293_CR4","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","volume":"123","author":"J Zhang","year":"2014","unstructured":"Zhang J, Jima D, Moffitt AB, Liu Q, Czader M, Hsi ED, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014;123(19):2988\u201396.","journal-title":"Blood"},{"issue":"2","key":"293_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","volume":"2","author":"W Klapper","year":"2009","unstructured":"Klapper W, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop. 2009;2(2):103\u201311.","journal-title":"J Hematop"},{"issue":"1","key":"293_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","volume":"13","author":"W Hanel","year":"2020","unstructured":"Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"293_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrm3011","volume":"11","author":"JR Gareau","year":"2010","unstructured":"Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol. 2010;11(12):861\u201371.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"293_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cell.2012.10.021","volume":"151","author":"I Psakhye","year":"2012","unstructured":"Psakhye I, Jentsch S. Protein group modification and synergy in the SUMO pathway as exemplified in DNA repair. Cell. 2012;151(4):807\u201320.","journal-title":"Cell"},{"issue":"4","key":"293_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/nprot.2014.053","volume":"9","author":"SV Barysch","year":"2014","unstructured":"Barysch SV, Dittner C, Flotho A, Becker J, Melchior F. Identification and analysis of endogenous SUMO1 and SUMO2\/3 targets in mammalian cells and tissues using monoclonal antibodies. Nat Protoc. 2014;9(4):896\u2013909.","journal-title":"Nat Protoc"},{"issue":"6","key":"293_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.trecan.2020.11.009","volume":"7","author":"JS Kroonen","year":"2020","unstructured":"Kroonen JS, Vertegaal ACO. Targeting SUMO signaling to wrestle cancer. Trends Cancer. 2020;7(6):496\u2013510.","journal-title":"Trends Cancer."},{"issue":"11","key":"293_CR11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2217\/fon.15.41","volume":"11","author":"D Mattoscio","year":"2015","unstructured":"Mattoscio D, Chiocca S. SUMO pathway components as possible cancer biomarkers. Future Oncol. 2015;11(11):1599\u2013610.","journal-title":"Future Oncol"},{"issue":"16","key":"293_CR12","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.3390\/ijms20163895","volume":"20","author":"M Boulanger","year":"2019","unstructured":"Boulanger M, Paolillo R, Piechaczyk M, Bossis G. The SUMO pathway in hematomalignancies and their response to therapies. Int J Mol Sci. 2019;20(16):3895.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"293_CR13","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1182\/blood-2014-06-584524","volume":"124","author":"A Hoellein","year":"2014","unstructured":"Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, et al. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 2014;124(13):2081\u201390.","journal-title":"Blood"},{"issue":"4","key":"293_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11523-010-0165-2","volume":"5","author":"JJ Driscoll","year":"2010","unstructured":"Driscoll JJ, Dechowdhury R. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy. Target Oncol. 2010;5(4):281\u20139.","journal-title":"Target Oncol"},{"issue":"2","key":"293_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2005.01.005","volume":"7","author":"J Zhu","year":"2005","unstructured":"Zhu J, Zhou J, Peres L, Riaucoux F, Honore N, Kogan S, et al. A sumoylation site in PML\/RARA is essential for leukemic transformation. Cancer Cell. 2005;7(2):143\u201353.","journal-title":"Cancer Cell"},{"issue":"5","key":"293_CR16","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1021\/acs.jmedchem.0c01491","volume":"64","author":"SP Langston","year":"2021","unstructured":"Langston SP, Grossman S, England D, Afroze R, Bence N, Bowman D, et al. Discovery of TAK-981, a first-in-class inhibitor of SUMO-activating enzyme for the treatment of cancer. J Med Chem. 2021;64(5):2501\u201320.","journal-title":"J Med Chem"},{"issue":"611","key":"293_CR17","doi-asserted-by":"publisher","first-page":"eaba7791","DOI":"10.1126\/scitranslmed.aba7791","volume":"13","author":"ES Lightcap","year":"2021","unstructured":"Lightcap ES, Yu P, Grossman S, Song K, Khattar M, Xega K, et al. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models. Sci Transl Med. 2021;13(611):eaba7791.","journal-title":"Sci Transl Med."},{"issue":"1","key":"293_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-021-02226-9","volume":"41","author":"L Du","year":"2022","unstructured":"Du L, Liu W, Aldana-Masangkay G, Pozhitkov A, Pichiorri F, Chen Y, et al. SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma. J Exp Clin Cancer Res. 2022;41(1):8.","journal-title":"J Exp Clin Cancer Res"},{"key":"293_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324834","author":"S Kumar","year":"2022","unstructured":"Kumar S, Schoonderwoerd MJA, Kroonen JS, de Graaf IJ, Sluijter M, Ruano D, et al. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2021-324834.","journal-title":"Gut"},{"issue":"10","key":"293_CR20","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.4049\/jimmunol.1502193","volume":"197","author":"KY Su","year":"2016","unstructured":"Su KY, Watanabe A, Yeh CH, Kelsoe G, Kuraoka M. Efficient culture of human naive and memory B cells for use as APCs. J Immunol. 2016;197(10):4163\u201376.","journal-title":"J Immunol"},{"issue":"24","key":"293_CR21","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","volume":"128","author":"D Chiron","year":"2016","unstructured":"Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128(24):2808\u201318.","journal-title":"Blood"},{"issue":"6","key":"293_CR22","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-13-0987","volume":"20","author":"JC Godbersen","year":"2014","unstructured":"Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, et al. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-kappaB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014;20(6):1576\u201389.","journal-title":"Clin Cancer Res"},{"issue":"38","key":"293_CR23","doi-asserted-by":"publisher","first-page":"25332","DOI":"10.18632\/oncotarget.25011","volume":"9","author":"MI Merolle","year":"2018","unstructured":"Merolle MI, Ahmed M, Nomie K, Wang ML. The B cell receptor signaling pathway in mantle cell lymphoma. Oncotarget. 2018;9(38):25332\u201341.","journal-title":"Oncotarget"},{"issue":"2","key":"293_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3(2):185\u201397.","journal-title":"Cancer Cell"},{"issue":"12","key":"293_CR25","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.4161\/cc.24928","volume":"12","author":"D Chiron","year":"2013","unstructured":"Chiron D, Martin P, Di Liberto M, Huang X, Ely S, Lannutti BJ, et al. Induction of prolonged early G1 arrest by CDK4\/CDK6 inhibition reprograms lymphoma cells for durable PI3Kdelta inhibition through PIK3IP1. Cell Cycle. 2013;12(12):1892\u2013900.","journal-title":"Cell Cycle"},{"issue":"34","key":"293_CR26","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1038\/onc.2013.546","volume":"33","author":"SS Myatt","year":"2014","unstructured":"Myatt SS, Kongsema M, Man CW, Kelly DJ, Gomes AR, Khongkow P, et al. SUMOylation inhibits FOXM1 activity and delays mitotic transition. Oncogene. 2014;33(34):4316\u201329.","journal-title":"Oncogene"},{"issue":"6","key":"293_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.molcel.2008.01.013","volume":"29","author":"XD Zhang","year":"2008","unstructured":"Zhang XD, Goeres J, Zhang H, Yen TJ, Porter AC, Matunis MJ. SUMO-2\/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Mol Cell. 2008;29(6):729\u201341.","journal-title":"Mol Cell"},{"issue":"6","key":"293_CR28","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.molcel.2014.02.001","volume":"53","author":"J Schimmel","year":"2014","unstructured":"Schimmel J, Eifler K, Sigurethsson JO, Cuijpers SA, Hendriks IA, Verlaan-de Vries M, et al. Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. Mol Cell. 2014;53(6):1053\u201366.","journal-title":"Mol Cell"},{"issue":"12","key":"293_CR29","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.tibs.2015.09.006","volume":"40","author":"K Eifler","year":"2015","unstructured":"Eifler K, Vertegaal ACO. SUMOylation-mediated regulation of cell cycle progression and cancer. Trends Biochem Sci. 2015;40(12):779\u201393.","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"293_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrc2608","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer. 2009;9(5):327\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"293_CR31","doi-asserted-by":"publisher","first-page":"12131","DOI":"10.1073\/pnas.2001760117","volume":"117","author":"CF Nielsen","year":"2020","unstructured":"Nielsen CF, Zhang T, Barisic M, Kalitsis P, Hudson DF. Topoisomerase IIalpha is essential for maintenance of mitotic chromosome structure. Proc Natl Acad Sci U S A. 2020;117(22):12131\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"293_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cell.2008.01.045","volume":"133","author":"MM Dawlaty","year":"2008","unstructured":"Dawlaty MM, Malureanu L, Jeganathan KB, Kao E, Sustmann C, Tahk S, et al. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell. 2008;133(1):103\u201315.","journal-title":"Cell"},{"issue":"4","key":"293_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/21541264.2017.1311829","volume":"8","author":"E Rosonina","year":"2017","unstructured":"Rosonina E, Akhter A, Dou Y, Babu J, Sri Theivakadadcham VS. Regulation of transcription factors by sumoylation. Transcription. 2017;8(4):220\u201331.","journal-title":"Transcription"},{"issue":"6","key":"293_CR34","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.devcel.2017.05.022","volume":"41","author":"S Santaguida","year":"2017","unstructured":"Santaguida S, Richardson A, Iyer DR, M\u2019Saad O, Zasadil L, Knouse KA, et al. Chromosome mis-segregation generates cell-cycle-arrested cells with complex karyotypes that are eliminated by the immune system. Dev Cell. 2017;41(6):638-51 e5.","journal-title":"Dev Cell"},{"issue":"7668","key":"293_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie KJ, Carroll P, Martin CA, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548(7668):461\u20135.","journal-title":"Nature"},{"issue":"6102","key":"293_CR36","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1126\/science.1224922","volume":"337","author":"L Senovilla","year":"2012","unstructured":"Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012;337(6102):1678\u201384.","journal-title":"Science"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-022-00293-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-022-00293-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-022-00293-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T05:20:35Z","timestamp":1657689635000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-022-00293-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1186\/s40164-022-00293-y","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"24 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Primary MCL samples were obtained following written informed consent under a protocol approved by the Institutional Review Board of The Ohio State University in accordance with the Declaration of Helsinki. All animal studies were approved by the OSU Institutional Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.H. was an employee of, and stockholder in, Takeda Pharmaceutical Company Limited while engaged in the research project. A.V.D. has received consulting fees from Abbvie, AstraZeneca, BeiGene, Genentech, Pharmacyclics and TG Therapeutics and has ongoing research funding from AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, MEI Pharma, SecuraBio, TG Therapeutics and Takeda Oncology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}